OTC: MDCLF - MedinCell S.A.

Rentabilité sur six mois: 0%
Secteur: Healthcare

Calendrier des promotions MedinCell S.A.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise

MedinCell S.A. develops various therapeutic solutions in France. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients.

plus de détails
The company's products in development include mdc-IRM, a risperidone extended-release injectable suspension completed Phase III trial for use in the treatment of schizophrenia; mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain & inflammation; and mdc-TJK, a subcutaneous injection in Phase III trials for use in the treatment of schizophrenia. Its product candidates in preclinical trials, such as mdc-ANG, an antipsychotic product for use in the treatment of schizophrenia; mdc-TTG for Covid-19 and its variants; mdc-GRT for use in organ transplant; mdc-WWM for contraception; mdc-STM for use in malaria; mdc-KPT for use in acute pain for pets; and mdc-IRM for use in neuroscience. The company was incorporated in 2003 and is based in Jacou, France.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета eur
Сайт https://www.medincell.com
Changement de prix par jour: 0% (6.976)
Changement de prix par semaine: 0% (6.976)
Changement de prix par mois: 0% (6.976)
Changement de prix sur 3 mois: 0% (6.976)
Changement de prix sur six mois: 0% (6.976)
Changement de prix par an: 0% (6.976)
Evolution du prix sur 3 ans: -50.17% (14)
Evolution du prix sur 5 ans: 0% (6.976)
Evolution des prix sur 10 ans: 0% (6.976)
Evolution des prix depuis le début de l'année: 0% (6.976)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 19.97 1
P/BV -4.48 0
P/E 0 0
EV/EBITDA -11.95 0
Total: 2.63

Efficacité

Nom Signification Grade
ROA, % -75.54 0
ROE, % 60.25 10
Total: 1.67

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Devoir

Nom Signification Grade
Debt/EBITDA -3.17 10
Total: 7.4

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % 221.18 10
Rentabilité Ebitda, % 3.76 1
Rentabilité EPS, % -35.02 0
Total: 2.4
Plus de détails

Établissements Volume Partager, %
American Funds Insurance Ser-Global Small Capitalization Fund 397121 1.58



Superviseur Titre d'emploi Paiement Année de naissance
Mr. Christophe Douat Chief Executive Officer & Director 427.7k 1966 (59 années)
Mr. Franck Pouzache Chief People Officer & Member of the Management Board 216.57k
Julie Alimi Head of Legal N/A
Mr. David Heuze Head of Communications N/A
Mr. Adolfo Lopez-Noriega Head of Research & Development N/A
Mr. Sebastien Enault Chief Business Officer N/A
Ms. Helen Martin Head of Alliance & Project Management N/A
Ms. Quiterie De Beauregard Head of Global Health Development N/A
Dr. Richard Malamut M.D. Chief Medical Officer N/A 1960 (65 années)
Mr. Stephane Postic Chief Financial Officer

Adresse: France, Jacou, 3 rue des Frères Lumière - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://www.medincell.com